US4749576A
(en)
*
|
1984-05-10 |
1988-06-07 |
Ciba-Geigy Corporation |
Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
|
JPS61218517A
(ja)
*
|
1985-03-25 |
1986-09-29 |
Bio Materiaru Yunibaasu:Kk |
経皮吸収製剤
|
FR2585246A1
(fr)
*
|
1985-07-26 |
1987-01-30 |
Cortial |
Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
|
US4794002A
(en)
*
|
1985-11-01 |
1988-12-27 |
Monsanto Company |
Modified polymeric surfaces and process for preparing same
|
JPH0643851B2
(ja)
*
|
1986-03-13 |
1994-06-08 |
大同メタル工業株式会社 |
軸受ユニット
|
US4983400A
(en)
*
|
1986-06-16 |
1991-01-08 |
Merck & Co., Inc. |
Controlled release combination of carbidopa/levodopa
|
US4780236A
(en)
*
|
1986-06-20 |
1988-10-25 |
Kiwi Brands, Inc. |
Lavoratory cleansing block containing polyethylene gycol disteatrate, guar gum and sodium chloride
|
US4743248A
(en)
*
|
1986-08-11 |
1988-05-10 |
Alza Corporation |
Dosage form for delivering acid sensitive beneficial agent
|
GB8620845D0
(en)
*
|
1986-08-28 |
1986-10-08 |
Reckitt & Colmann Prod Ltd |
Treatment of textile surfaces
|
US5219575A
(en)
*
|
1987-06-26 |
1993-06-15 |
Duphar International Research B.V. |
Compositions with controlled zero-order delivery rate and method of preparing these compositions
|
EP0297650A1
(de)
*
|
1987-06-26 |
1989-01-04 |
Duphar International Research B.V |
Zusammensetzungen mit Freisetzung nullter Ordnung und Verfahren zu ihrer Herstellung
|
US4910015A
(en)
*
|
1987-10-19 |
1990-03-20 |
Massachusetts Institute Of Technology |
Surface-active polysiloxanes and drug releasing materials thereof
|
GB8801863D0
(en)
*
|
1988-01-28 |
1988-02-24 |
Fulmer Yarsley Ltd |
Pharmaceutical formulations with controlled drug release
|
US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
DE69603577T2
(de)
|
1995-02-10 |
1999-11-25 |
Medtronic Inc |
Verfahren und vorrichtung zur verabreichung von analgetika
|
US5945125A
(en)
*
|
1995-02-28 |
1999-08-31 |
Temple University |
Controlled release tablet
|
US20030203036A1
(en)
|
2000-03-17 |
2003-10-30 |
Gordon Marc S. |
Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
|
GB9703673D0
(en)
*
|
1997-02-21 |
1997-04-09 |
Bradford Particle Design Ltd |
Method and apparatus for the formation of particles
|
US6039968A
(en)
*
|
1997-06-24 |
2000-03-21 |
Hoechst Marion Roussel |
Intravaginal drug delivery device
|
DE19843904A1
(de)
*
|
1998-09-24 |
2000-03-30 |
Basf Ag |
Feste Dosierungsform mit polymerem Bindemittel
|
DE19843903A1
(de)
*
|
1998-09-24 |
2000-03-30 |
Basf Ag |
Feste Dosierungsform mit copolymerem Bindemittel
|
US6706283B1
(en)
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
US7943162B2
(en)
*
|
1999-10-21 |
2011-05-17 |
Alcon, Inc. |
Drug delivery device
|
KR100523127B1
(ko)
|
1999-12-23 |
2005-10-20 |
화이자 프로덕츠 인코포레이티드 |
하이드로겔계 약물 투여 형태
|
US20030086972A1
(en)
*
|
2000-08-09 |
2003-05-08 |
Appel Leah E. |
Hydrogel-driven drug dosage form
|
GB0027357D0
(en)
*
|
2000-11-09 |
2000-12-27 |
Bradford Particle Design Plc |
Particle formation methods and their products
|
WO2003009784A1
(en)
*
|
2001-07-23 |
2003-02-06 |
Alcon, Inc. |
Ophthalmic drug delivery device
|
CN1203814C
(zh)
|
2001-07-23 |
2005-06-01 |
爱尔康公司 |
眼部药物输送装置
|
ES2663873T3
(es)
*
|
2001-10-29 |
2018-04-17 |
Massachusetts Institute Of Technology |
Forma farmacéutica con perfil de liberación de orden cero fabricada por impresión tridimensional
|
GB0216562D0
(en)
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
GB0310636D0
(en)
*
|
2003-05-08 |
2003-06-11 |
Nektar Therapeutics Uk Ltd |
Particulate materials
|
KR20060015587A
(ko)
|
2003-05-08 |
2006-02-17 |
넥타 쎄라퓨틱스 유케이 리미티드 |
미립물
|
CA2522592A1
(en)
*
|
2003-07-10 |
2005-02-03 |
Alcon, Inc. |
Ophthalmic drug delivery device
|
US20060246109A1
(en)
*
|
2005-04-29 |
2006-11-02 |
Hossainy Syed F |
Concentration gradient profiles for control of agent release rates from polymer matrices
|
WO2007038686A2
(en)
*
|
2005-09-27 |
2007-04-05 |
Tissuetech, Inc. |
Amniotic membrane preparations and purified compositions and methods of use
|
US8187639B2
(en)
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
EP1959966B1
(de)
|
2005-11-28 |
2020-06-03 |
Marinus Pharmaceuticals, Inc. |
Ganaxolon-formulierungen und verfahren zu ihrer herstellung und verwendung
|
US8246973B2
(en)
|
2006-06-21 |
2012-08-21 |
Advanced Cardiovascular Systems, Inc. |
Freeze-thaw method for modifying stent coating
|
CN101528830A
(zh)
|
2006-07-10 |
2009-09-09 |
麦德医像公司 |
超弹性环氧水凝胶
|
ATE510538T1
(de)
|
2006-08-11 |
2011-06-15 |
Univ Johns Hopkins |
Zusammensetzungen und verfahren für nervenschutz
|
ATE531263T1
(de)
|
2006-09-22 |
2011-11-15 |
Pharmacyclics Inc |
Hemmer der bruton-tyrosinkinase
|
JP5411141B2
(ja)
|
2007-09-10 |
2014-02-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
US9995295B2
(en)
|
2007-12-03 |
2018-06-12 |
Medipacs, Inc. |
Fluid metering device
|
WO2010027875A2
(en)
|
2008-08-27 |
2010-03-11 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
EP2421901B1
(de)
|
2009-04-24 |
2015-10-28 |
Tissue Tech, Inc. |
Zusammensetzungen mit hc-ha-komplex und verfahren zu ihrer verwendung
|
US9238102B2
(en)
|
2009-09-10 |
2016-01-19 |
Medipacs, Inc. |
Low profile actuator and improved method of caregiver controlled administration of therapeutics
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
US9500186B2
(en)
|
2010-02-01 |
2016-11-22 |
Medipacs, Inc. |
High surface area polymer actuator with gas mitigating components
|
EP2558866B1
(de)
|
2010-04-15 |
2016-08-17 |
Tracon Pharmaceuticals, Inc. |
Potenzierung einer antikrebs-wirkung durch eine kombinationstherapie mit ber-pfad-hemmern
|
JP2013525448A
(ja)
|
2010-04-27 |
2013-06-20 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
WO2011139489A2
(en)
|
2010-04-27 |
2011-11-10 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
CA2800913C
(en)
|
2010-06-03 |
2019-07-23 |
Pharmacyclics, Inc. |
The use of inhibitors of bruton's tyrosine kinase (btk)
|
MX337711B
(es)
|
2010-08-27 |
2016-03-15 |
Calcimedica Inc |
Compuestos que modulan el calcio intracelular.
|
WO2012061556A1
(en)
|
2010-11-03 |
2012-05-10 |
Flugen, Inc. |
Wearable drug delivery device having spring drive and sliding actuation mechanism
|
US9808030B2
(en)
|
2011-02-11 |
2017-11-07 |
Grain Processing Corporation |
Salt composition
|
WO2012149486A1
(en)
|
2011-04-28 |
2012-11-01 |
Tissuetech, Inc. |
Methods of modulating bone remodeling
|
EP2717888B1
(de)
|
2011-06-10 |
2020-09-09 |
Tissuetech, Inc. |
Verfahren zur verarbeitung fötaler gewebesubstrate
|
SG2014014419A
(en)
|
2011-09-13 |
2014-07-30 |
Pharmacyclics Inc |
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
EP3698782A1
(de)
|
2012-01-06 |
2020-08-26 |
Lundbeck La Jolla Research Center, Inc. |
Carbamatverbindungen zur verwendung in therapie
|
US10000605B2
(en)
|
2012-03-14 |
2018-06-19 |
Medipacs, Inc. |
Smart polymer materials with excess reactive molecules
|
MA37711A1
(fr)
|
2012-06-04 |
2017-05-31 |
Pharmacyclics Inc |
Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
|
CA2878163A1
(en)
|
2012-07-11 |
2014-01-16 |
Tissuetech, Inc. |
Compositions containing hc-ha/ptx3 complexes and methods of use thereof
|
EP2900674B1
(de)
|
2012-09-28 |
2017-05-31 |
University of Washington through its Center for Commercialization |
Verbindungen und verfahren zur vorbeugung, behandlung und/oder schutz vor haarzelltod
|
WO2014059333A1
(en)
|
2012-10-12 |
2014-04-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
AU2014360446A1
(en)
|
2013-12-05 |
2016-06-09 |
Pharmacyclics, Llc |
Inhibitors of Bruton's tyrosine kinase
|
WO2015164213A1
(en)
|
2014-04-23 |
2015-10-29 |
The Research Foundation For The State University Of New York |
A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
|
TW201603818A
(zh)
|
2014-06-03 |
2016-02-01 |
組織科技股份有限公司 |
組成物及方法
|
US9775978B2
(en)
|
2014-07-25 |
2017-10-03 |
Warsaw Orthopedic, Inc. |
Drug delivery device and methods having a retaining member
|
US9764122B2
(en)
|
2014-07-25 |
2017-09-19 |
Warsaw Orthopedic, Inc. |
Drug delivery device and methods having an occluding member
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
US10399994B2
(en)
|
2015-02-06 |
2019-09-03 |
University Of Washington |
Compounds and methods for preventing or treating sensory hair cell death
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
WO2016138025A2
(en)
|
2015-02-23 |
2016-09-01 |
Tissuetech, Inc. |
Apparatuses and methods for treating ophthalmic diseases and disorders
|
JP2018510138A
(ja)
|
2015-02-27 |
2018-04-12 |
カーテナ ファーマシューティカルズ,インク. |
Olig2活性の阻害
|
BR122023020985A2
(pt)
|
2015-03-03 |
2023-12-26 |
Pharmacyclics Llc |
Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton
|
MA41827A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
|
MA41828A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
MX2017014344A
(es)
|
2015-05-11 |
2018-04-11 |
Abide Therapeutics Inc |
Metodos para el tratamiento de la inflacion o el dolor neuropatico.
|
WO2016187555A1
(en)
|
2015-05-20 |
2016-11-24 |
Tissuetech, Inc. |
Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
|
WO2017040617A1
(en)
|
2015-08-31 |
2017-03-09 |
Pharmacyclics Llc |
Btk inhibitor combinations for treating multiple myeloma
|
US10076650B2
(en)
|
2015-11-23 |
2018-09-18 |
Warsaw Orthopedic, Inc. |
Enhanced stylet for drug depot injector
|
US10975149B2
(en)
|
2015-12-16 |
2021-04-13 |
The Walter And Eliza Hall Institute Of Medical Research |
Inhibition of cytokine-induced SH2 protein in NK cells
|
BR112018014590A2
(pt)
|
2016-01-19 |
2018-12-11 |
Janssen Pharmaceutica Nv |
formulações/composições compreendendo um inibidor de btk
|
CN108472258A
(zh)
|
2016-01-19 |
2018-08-31 |
詹森药业有限公司 |
包含btk抑制剂的配制品/组合物
|
TW201733600A
(zh)
|
2016-01-29 |
2017-10-01 |
帝聖工業公司 |
胎兒扶持組織物及使用方法
|
US10851123B2
(en)
|
2016-02-23 |
2020-12-01 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
WO2017176652A2
(en)
|
2016-04-04 |
2017-10-12 |
Sinopia Biosciences, Inc. |
Treating extrapyramidal syndrome using trapidil
|
CN109562281B
(zh)
|
2016-05-25 |
2021-12-17 |
同心镇痛药物公司 |
酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
US10549081B2
(en)
|
2016-06-23 |
2020-02-04 |
Warsaw Orthopedic, Inc. |
Drug delivery device and methods having a retaining member
|
US11090702B2
(en)
*
|
2016-06-28 |
2021-08-17 |
Trustees Of Tufts College |
Compositions and methods for delivery of active agents
|
EP3484862B1
(de)
|
2016-07-18 |
2021-09-01 |
Arthrosi Therapeutics, Inc. |
Verbindungen, zusammensetzungen und verfahren zur behandlung oder prävention eines symptoms im zusammenhang mit gicht oder hyperurikämie
|
CN109843868A
(zh)
|
2016-08-26 |
2019-06-04 |
科泰纳制药公司 |
Olig2活性的抑制
|
US10434261B2
(en)
|
2016-11-08 |
2019-10-08 |
Warsaw Orthopedic, Inc. |
Drug pellet delivery system and method
|
SI3541807T1
(sl)
|
2016-11-16 |
2022-01-31 |
H. Lundbeck A/S |
Kristalinična oblika zaviralca MAGL
|
KR20190085046A
(ko)
|
2016-11-16 |
2019-07-17 |
어바이드 테라퓨틱스, 인크. |
약학 제제
|
AU2018325267B2
(en)
|
2017-09-01 |
2023-03-30 |
University Of Washington |
Crystalline forms of compounds for preventing or treating sensory hair cell death
|
WO2019169112A1
(en)
|
2018-02-28 |
2019-09-06 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
JP2021532183A
(ja)
|
2018-07-27 |
2021-11-25 |
コンセントリック アナルジェジクス,インク. |
フェノール性trpv1アゴニストのpeg化プロドラッグ
|
JP2022516057A
(ja)
|
2018-12-31 |
2022-02-24 |
バイオメア フュージョン,エルエルシー |
メニン-mll相互作用の不可逆的阻害剤
|
EP3937938A1
(de)
|
2019-03-15 |
2022-01-19 |
Unicycive Therapeutics Inc. |
Nicorandilderivate
|
MX2022013224A
(es)
|
2020-04-21 |
2022-11-14 |
H Lundbeck As |
Sintesis de un inhibidor de la monoacilglicerol lipasa.
|
EP4263542A1
(de)
|
2020-12-16 |
2023-10-25 |
Biomea Fusion, Inc. |
Kondensierte pyrimidinverbindungen als inhibitoren der menin-mll-interaktion
|
WO2022150525A1
(en)
|
2021-01-06 |
2022-07-14 |
Awakn Life Sciences |
Mdma in the treatment of alcohol use disorder
|
CA3218884A1
(en)
|
2021-05-11 |
2022-11-17 |
David Nutt |
Therapeutic aminoindane compounds and compositions
|
IL309073A
(en)
|
2021-06-03 |
2024-02-01 |
Arcadia Medicine Inc |
Enantiomeric entactogen compounds and methods of their use.
|
US20230120115A1
(en)
|
2021-08-11 |
2023-04-20 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
AU2022331496A1
(en)
|
2021-08-20 |
2024-02-29 |
Biomea Fusion, Inc. |
Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
TW202340177A
(zh)
|
2021-12-30 |
2023-10-16 |
美商拜歐米富士恩股份有限公司 |
作為 flt3抑制劑之吡嗪化合物
|
WO2023139163A1
(en)
|
2022-01-19 |
2023-07-27 |
Awakn Ls Europe Holdings Limited |
1,3-benzodioxole esters and their therapeutic use
|
WO2023156565A1
(en)
|
2022-02-16 |
2023-08-24 |
Awakn Ls Europe Holdings Limited |
Bridged ring compounds and their therapeutic use as cns agents
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
US20240010649A1
(en)
|
2022-07-06 |
2024-01-11 |
Oppilan Pharma Limited |
Crystalline forms of an s1p receptor modulator
|